Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Oncology Institute (TOI) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • Oncology Institute's Treasury Shares changed 0.0% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.0 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Treasury Shares is $1.7 million, which was up 1861.52% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Treasury Shares registered a high of $3.6 million during Q1 2023, and its lowest value of $1.4 million during Q2 2021.
  • Over the past 5 years, Oncology Institute's median Treasury Shares value was $1.7 million (recorded in 2023), while the average stood at $1.9 million.
  • Within the past 5 years, the most significant YoY rise in Oncology Institute's Treasury Shares was 1398.21% (2024), while the steepest drop was 0.0% (2024).
  • Quarter analysis of 3 years shows Oncology Institute's Treasury Shares stood at $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Its Treasury Shares was $1.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and $1.0 million in Q1 2025.